KRAS and non-small cell lung carcinoma: Hence, as peptides derived from the KRASG12V mutation represent truly specific neoantigens in NSCLC and PDAC, and the development of a TCRm CAR recognizing mutated KRAS/HLA-A11 was recently described [50], we explored two different TCRm CARs, composed of the KRASG12V/HLA-A2 complex recognizing scFv D10 [28], either linked to a human IgFc [29] or to the recently described STII spacer [30] to investigate immunity to a KRASG12V5-14/HLA-A2 peptide complex.